Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer
January 05 2022 - 4:05PM
Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading
point-of-care diagnostics company focused on infectious diseases,
today announced the appointment of Larry Steenvoorden as Chief
Financial Officer effective immediately.
“We are thrilled to welcome Larry to the Chembio
executive leadership team. Larry has developed valuable insights
over his 25 years of financial leadership experience, spanning
accounting, budgeting, public company reporting, business
development, and commercial strategy. Those skills will be critical
to our success as we scale our business in support of our corporate
growth and operational objectives,” said Richard Eberly, Chembio’s
President and Chief Executive Officer. “We look forward to working
with Larry and are confident his prior roles, particularly as a
financial executive at a large publicly traded healthcare
conglomerate, make him a perfect fit for Chembio.”
Mr. Steenvoorden served as a Senior Director at
Accordion Partners, providing CFO advisory services to private
equity backed companies for the past four years, and as the Chief
Accounting and Financial Officer for Onyx Renewable Partners for
the preceding two years. Previously, Mr. Steenvoorden had a 15-year
career at Siemens holding roles of increasing responsibility,
ultimately as Global Controller & Vice President, Business
Planning & Controlling for Siemens Healthcare Diagnostics. In
this role he was responsible for financial planning, accounting and
controlling functions, operations, and regional reporting, mergers
and acquisitions, integrations, and external reporting. His
responsibilities also included commercial strategy, business
operations management, and cost reduction initiatives across the
entire healthcare medical device, point-of-care manufacturing
business. Mr. Steenvoorden is a Certified Public Accountant, and he
received his Bachelor of Science in Accounting from the University
of Delaware and his Master of Business Administration from Rider
University.
“Chembio offers an advanced point-of-care testing
platform that delivers multiplexed, accurate, rapid and actionable
results that enable healthcare providers to more efficiently manage
patients to improve outcomes across decentralized healthcare
facilities,” said Mr. Steenvoorden. “As healthcare continues to
shift to decentralized settings, Chembio’s tests are well
positioned to provide value as this market grows. I am excited to
contribute to an organization focused on improving healthcare
outcomes for patients worldwide.”
About Chembio DiagnosticsChembio
is a leading diagnostics company focused on developing and
commercializing point-of-care tests used for the rapid detection
and diagnosis of infectious diseases, including sexually
transmitted disease, insect vector and tropical disease, COVID-19
and other viral and bacterial infections, enabling expedited
treatment. Coupled with Chembio’s extensive scientific expertise,
its novel DPP technology offers broad market applications beyond
infectious disease. Chembio’s products are sold globally, directly
and through distributors, to hospitals and clinics, physician
offices, clinical laboratories, public health organizations,
government agencies, and consumers. Learn more at
www.chembio.com.
DPP is Chembio’s registered trademark, and the Chembio logo is
Chembio’s trademark. For convenience, these trademarks appear in
this release without ® or ™ symbols, but that practice does not
mean that Chembio will not assert, to the fullest extent under
applicable law, its rights to the trademarks. All other
trademarks appearing in this release are the property of their
respective owners.
Contact: Philip Taylor Gilmartin
Group415-937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Sep 2023 to Sep 2024